Figure 5
From: A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
Therapeutic efficacy of the recombinant anti-CD20 mAb in treating B-cell lymphomas. Groups of 10 SCID mice were intravenously injected with 4 × 106 Raji cells. Seven days after tumour cell inoculation, the mice were treated with 100 μg/mouse of the recombinant mAb, Rituxan, or a saline control. The mice were monitored daily and euthanized at the onset of hind leg paralysis. (a) The body weight curve of tumour-bearing SCID mice treated with the anti-CD20 mAbs. *p < 0.05, **p < 0.01. (b) Survival curve of the tumour-bearing SCID mice treated with the anti-CD20 mAbs.
